COVID-19 Vaccine Booster Responses in Patients with Hematologic Malignancies

Serologic responses were similar to those in healthy controls overall but were poorer in some patients with B-cell malignancies.

Patients with hematologic malignancies have varying degrees of immunodeficiency related to the underlying disease and to anti-cancer therapy, with well-documented impairment of COVID-19 vaccine responses and an increased risk for severe or fatal COVID-19 infection. Investigators in the Netherlands assessed humoral anti-spike glycoprotein (S1) and nucleoprotein responses to a third dose of the COVID-19 mRNA-1273 (Moderna) vaccine in patients with hematologic malignancy. The third dose was given 5 months after completion of the standard two-dose schedule.

Both SARS-CoV-2 antibody response and neutralizing capacity against the wild type and variant COVID-19 strains were determined and compared with responses in a cohort of randomly selected, ag…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

COVID-19 Vaccine Booster Responses in Patients with Hematologic Malignancies

Topics

Reviewing Author